SanBio Co (4592) AI Stock Analysis

• Market Cap: ¥138.27B
• Dividend Yield: N/A
• Average Volume (3M): 2.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: N/A
• EPS Growth: -12.69%
• Country: JP
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 78,033,330
• 10 Day Avg. Volume: 2,869,570
• 30 Day Avg. Volume: 2,080,090
• PEG Ratio: -1.38
• Price to Book (P/B): 9.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,866.67
• Price Target Upside: -16.29% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ¥1,852.00 ▼(-16.95% Downside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn) and bearish technical conditions (price below key moving averages and negative MACD). Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.

Positive Factors

Balance sheet improvement

Recent equity growth and asset expansion have improved solvency on paper, reducing immediate liquidity pressure and extending runway versus peers. Manageable debt-to-equity in 2023–2025 (~0.21–0.24) implies limited leverage under normal conditions, supporting financing flexibility.

Proprietary CNS cell-therapy focus

A concentrated cell-therapy platform targeting CNS disorders creates a durable competitive position: technical specialization raises entry barriers, aligns R&D efforts, and enhances potential for valuable IP or strategic partnerships if clinical programs advance, supporting long-term upside.

Improving cash burn trend

Year-over-year reduction from peak cash burn suggests management may be moderating spend or improving operational efficiency. If this trend continues, it can lengthen the financing runway, reduce near-term dilution risk, and improve the company's ability to execute programs without constant refinancing.

Negative Factors

No commercial revenue

The company remains pre-revenue with persistent large net losses and deeply negative EBIT, indicating it has not established a commercial earnings base. Long-term value is therefore contingent on successful clinical outcomes or licensing, which increases binary execution risk for investors and creditors.

Persistent negative cash flow

Sustained negative operating and free cash flow demonstrates ongoing cash burn and structural funding needs. This compels repeated access to external capital or partnerships, raising dilution and refinancing risk and potentially forcing program delays or reprioritization if financing conditions tighten.

Financing volatility risk

A prior sharp increase in leverage shows the capital structure can deteriorate rapidly under funding stress. That history signals the company may face abrupt refinancing or covenant pressure in adverse scenarios, limiting strategic optionality and increasing downside risk during clinical or market setbacks.

SanBio Co Business Overview & Revenue Model

Company Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

How the Company Makes Money

null

SanBio Co Financial Statement Overview

Summary

Overall financial profile is weak: revenue is 0 across years, with persistent large net losses and deeply negative EBIT. Cash flow is also weak with sustained negative operating/free cash flow, indicating ongoing cash burn and funding needs. The balance sheet is comparatively better (higher equity recently and moderate leverage in the latest periods), but losses keep returns on equity deeply negative.

Income Statement

The income statement is very weak: revenue is consistently 0 across all annual periods, while losses remain large (net income roughly -¥2.6B to -¥5.6B historically, and about -¥3.8B in the latest year). Operating losses are persistent (EBIT deeply negative each year), indicating the business has not yet established a scalable commercial earnings base. A modest positive is that losses narrowed versus the 2023 trough, but profitability remains far from breakeven and gross profit is negative, reinforcing the early-stage/clinical-stage risk profile.

Balance Sheet

The balance sheet is mixed but comparatively the strongest of the three. Leverage looks manageable in most years (debt-to-equity around ~0.21–0.24 in 2023–2025), though it spiked materially in 2022 (debt-to-equity ~1.24), showing financing risk can rise quickly. Equity increased sharply in the latest year (to ~¥13.6B) and assets expanded, which improves solvency on paper; however, returns on equity are consistently deeply negative due to ongoing losses, and the rising debt balance in the latest year signals continued reliance on external funding while profitability is absent.

Cash Flow

Cash flow quality is weak: operating cash flow and free cash flow are materially negative every year (roughly -¥3.6B to -¥7.5B), reflecting sustained cash burn typical of development-stage biotech. There is improvement from the worst burn levels seen in 2023, but the latest year still shows heavy outflows (operating cash flow about -¥3.8B; free cash flow about -¥3.8B). Free cash flow is broadly in line with net losses (i.e., losses are not merely accounting-driven), which underscores ongoing funding needs and dilution/refinancing risk.

Breakdown	TTM	Jan 2026	Jan 2025	Jan 2025	Jan 2024	Jan 2023
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-8.26M	-8.05M	-9.37M	-14.50M	-24.61M	-132.47M
EBITDA	-3.82B	-3.79B	-3.51B	-4.53B	-7.87B	-6.49B
Net Income	-3.57B	-3.84B	-2.88B	-2.64B	-5.56B	-4.68B
Balance Sheet
Total Assets	3.22B	15.62B	3.45B	5.05B	7.05B	5.51B
Cash, Cash Equivalents and Short-Term Investments	2.74B	15.08B	2.92B	4.45B	6.73B	4.56B
Total Debt	1.36B	1.24B	397.00M	665.00M	933.00M	2.52B
Total Liabilities	1.93B	2.02B	1.68B	2.25B	2.62B	3.48B
Stockholders Equity	1.29B	13.60B	1.76B	2.79B	4.43B	2.04B
Cash Flow
Free Cash Flow	0.00	-3.84B	-3.62B	-4.79B	-7.46B	-6.61B
Operating Cash Flow	0.00	-3.81B	-3.62B	-4.78B	-7.45B	-6.57B
Investing Cash Flow	0.00	-231.04M	-4.27M	-19.03M	-10.10M	-66.26M
Financing Cash Flow	0.00	16.01B	2.10B	2.38B	9.46B	-1.47B

SanBio Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2230.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4592, the sentiment is Negative. The current price of 2230 is above the 20-day moving average (MA) of 2104.80, above the 50-day MA of 2007.86, and below the 200-day MA of 2347.66, indicating a bearish trend. The MACD of -14.57 indicates Positive momentum. The RSI at 42.97 is Neutral, neither overbought nor oversold. The STOCH value of 19.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4592.

SanBio Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	56 Neutral	¥15.50B	120.78	―	―	1.24%	-33.41%
7774	54 Neutral	¥24.89B	-34.16	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥49.28B	-13.30	―	―	-82.33%	47.73%
7776	49 Neutral	¥11.35B	-8.14	―	―	-42.49%	-2.37%
4592	43 Neutral	¥138.27B	-35.18	-253.07%	―	―	-12.69%
4599	43 Neutral	¥17.55B	-11.30	―	―	―	11.34%

SanBio Co Corporate Events

SanBio to Restructure Capital to Eliminate Deficit and Boost Financial Flexibility

SanBio plans to reduce its stated capital by 1.7 billion yen and capital reserves by a similar amount, reallocating these funds to other capital surplus to eliminate a retained earnings deficit of 3.4 billion yen recorded at the end of the fiscal year. The measures, slated to take effect on June 5, 2026 pending shareholder approval, are designed to lower the company’s tax burden, clean up its balance sheet without altering total net assets or share count, and create a more flexible platform for future shareholder returns and capital policy, with no expected impact on current business performance.

The company will transfer the increased other capital surplus to retained earnings brought forward, bringing that balance to zero and formally covering the accumulated deficit. By restructuring equity in this way, SanBio seeks to strengthen its financial profile within the capital-intensive biotech industry, potentially improving its capacity to pursue strategic financing options and return capital to shareholders over time while maintaining stability for existing investors.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2054.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Books Foreign Exchange Losses and Financing Costs in FY2026 Results

SanBio Co., Ltd. reported several non-operating expenses for the fiscal year ending January 31, 2026, including ¥29 million in bond interest tied to convertible bonds with stock acquisition rights and a ¥45 million charge in financing expenses mainly from committed credit line fees. The company also incurred ¥94 million in stock issuance costs related to new share and bond offerings, and booked a ¥326 million foreign exchange loss on foreign currency loans to a subsidiary, partly offset by a ¥321 million foreign currency translation adjustment and recognition of negative ¥450 million in deferred income taxes linked to those foreign currency-denominated assets.

These items reflect the financial impact of SanBio’s ongoing funding and capital markets activities, as well as currency volatility affecting its cross-border intra-group financing. While the company has detailed that the net effect of these non-operating expenses and deferred tax adjustments will be reflected in its full-year earnings, investors will need to examine the latest consolidated financial results to assess how these charges influence profitability, capital structure, and future financing flexibility.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2054.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Deepens Losses but Fortifies Balance Sheet as It Awaits AKUUGO Revenue

SanBio reported another year of losses for the fiscal year ended January 31, 2026, posting an operating loss of ¥3.79 billion and net loss of ¥3.84 billion, while operating revenue remained at zero. Despite the continued red ink, the company’s financial position strengthened sharply, with total assets rising to ¥15.62 billion and net assets to ¥13.60 billion, largely supported by robust financing cash inflows of ¥15.96 billion.

The company forecasts deeper losses in the fiscal year ending January 31, 2027, projecting a full-year net loss of ¥5.64 billion and maintaining a zero-dividend policy as it prioritizes investment over shareholder payouts. Importantly, the forecast excludes any potential revenue from its AKUUGO therapy because pricing has not yet been set, suggesting earnings could improve once pricing is determined and sales begin, but leaving near-term visibility limited for investors.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2054.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Finalizes Employee Stock Option Terms for 75,000 Shares

SanBio has finalized the terms for a new stock option program, approving the issuance of 75,000 share acquisition rights tied to an equal number of common shares at an exercise price of 1,898 yen per share. All of the options will be granted to three employees, underscoring the company’s use of equity-based compensation to align key staff with shareholder interests and support talent retention during its growth phase in the competitive biotech market.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1815.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

SanBio Issues New Employee Stock Options to Support Long-Term Growth

SanBio has approved the issuance of its 36th series of share acquisition rights as part of its stock option program, granting up to 75,000 stock options linked to an equal number of common shares to three employees. The program is designed to strengthen employee motivation, support the recruitment and retention of key talent, and align staff incentives with the company’s medium- to long-term performance, thereby reinforcing corporate value and shareholder interests through equity-based compensation.

The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1651.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.